Evaluate the Effectiveness of Progestin-Primed Versus GnRH Antagonist Protocols in Vietnamese Women Undergoing In-vitro Fertilization
NCT ID: NCT06191809
Last Updated: 2024-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
200 participants
INTERVENTIONAL
2023-02-14
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Progestin-primed Ovarian Stimulation Protocol Versus GnRH Antagonist Protocol in Polycystic Ovary Syndrome Patients Undergoing IVF/ICSI Cycles
NCT05112692
Comparison of Progestin Primed Ovarian Stimulation (PPOS) vs.GnRH Antagonist Methods on IVF Outcomes
NCT06396390
PPOS vs GnRH Antagonist in Ovarian Stimulation (ProGanOS Study)
NCT06378268
Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
NCT04414761
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
NCT04108039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This was an open-label, randomized controlled trial conducted at the Assisted Reproduction Center of Tam Anh General Hospital. The study aimed to estimate the efficacy of the intervention (PPOS protocol) compared to a control group receiving a gonadotropin-releasing hormone (GnRH) antagonist protocol.
Sample size estimation
The sample size estimation procedure is detailed in the study protocol. In brief, the investigators conducted a simulation that implied the method by Cundill and Alexander (2015) with parameters derived from the clinical profile of 804 patients who underwent ovarian stimulation by two protocols at Tam Anh Hospital from January to October 2022. The procedure aimed to optimize non-inferiority testing on the difference in the quantity of retrieved oocytes between two groups, estimated by a Negative Binomial distribution. The simulation result indicated that a total sample size of 200 patients (n=100 for each treatment arm) would be required to achieve a statistical power of 0.8.
Recruitment of study participants
Infertile patients come for examination at the Assisted Reproduction Center of Tam Anh General Hospital, Hanoi, and the Assisted Reproduction and Graft Technology Center of Hanoi Medical University. In the basic infertility examination process at the hospital, the clinicians will consider the patient's inclusive and exclusive criteria. The clinicians will contact a research team member if the inclusive criteria are met. A research team member or hospital physician will invite the patient to participate, advise on the study procedure and the benefits and risks of participating, and answer any patient questions. If the patients agree to participate, they will consent to participate in the trial. Each participant will be randomly assigned to the treatment group using the PPOS protocol or the control group using the GnRH-ant regimen.
Treatment method
Ovarian stimulation protocols
Controlled ovarian hyperstimulation commenced on the second day of the menses utilizing recombinant follicle-stimulating hormone. In the gonadotropin-releasing hormone (GnRH) antagonist protocol group, pituitary suppression began on stimulation day six via daily 0.25 milligram GnRH antagonist administration (ganirelix or cetrorelix). In the progestin-primed ovarian stimulation (PPOS) group, 30mg/day of dydrogesterone was initiated on cycle day 2 through to trigger day.
Laboratory protocol
Oocyte-cumulus complexes were incubated for 2 hours in G-IVF medium (Vitrolife) using Origio benchtop incubators to complete nuclear maturation. After removing cumulus cells, denuded oocytes were evaluated under an inverted microscope to validate the achievement of metaphase II status, while degenerate, large, or severely dysmorphic oocytes were excluded. Intracytoplasmic sperm injection (ICSI) was executed 3-4 hours post-retrieval by experienced embryologists. Resultant zygotes were cultured in continuous single media (Fujifilm Irvine Scientific) within tri-gas incubators (37°C, 5% O2, 6% CO2) until day 3. Strict morphological criteria were enforced, only retaining normally fertilized two pronuclei zygotes while eliminating abnormal multinuclear embryos. Cleavage-stage quality was graded at 67-69 hours per Istanbul consensus based on cell number, fragmentation, multinucleation, and uniformity. On post-ICSI day 3, embryologists counseled patients on pursuing blastocyst culture versus cryopreservation. The morphology of the blastocysts was evaluated using the Gardner and Schoolcraft grading system, and embryos meeting the criteria of 3-6 AA/AB/BA blastocysts or 1-2 AA/AB embryos were classified as good quality.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PPOS protocol
Ovarian stimulation protocol used progestin as premature LH surge inhibitor
Controlled Ovarian Stimulation Protocol
Ovarian Stimulation Process:
* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.
* Monitor response with ultrasound \& hormones (E2, LH, P4).
* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.
* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.
* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).
* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).
Embryo Culture \& Monitoring:
* Fertilize with ICSI.
* Culture \& evaluate embryos (43-45 hours, day 3/5).
* Freeze all embryos.
GnRH-ant protocol
Ovarian stimulation protocol used GnRH antagonist as premature LH surge inhibitor
Controlled Ovarian Stimulation Protocol
Ovarian Stimulation Process:
* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.
* Monitor response with ultrasound \& hormones (E2, LH, P4).
* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.
* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.
* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).
* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).
Embryo Culture \& Monitoring:
* Fertilize with ICSI.
* Culture \& evaluate embryos (43-45 hours, day 3/5).
* Freeze all embryos.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Controlled Ovarian Stimulation Protocol
Ovarian Stimulation Process:
* Stimulate ovaries with FSH \& hMG (150-375 IU) starting day 2-3 of menstruation.
* Monitor response with ultrasound \& hormones (E2, LH, P4).
* GnRH-ant arm: Prevent LH surge with Cetrorelix (0.25mg) starting day 5.
* PPOS arm: Suppress LH with Dydrogesterone (10mg x 3/day) from day 1.
* Trigger ovulation when ≥2 follicles \>17mm (Triptorelin, hCG, or rhCG).
* Oocyte retrieval 36-38 hours later (\>10mm follicles aspirated).
Embryo Culture \& Monitoring:
* Fertilize with ICSI.
* Culture \& evaluate embryos (43-45 hours, day 3/5).
* Freeze all embryos.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women age 20 to 45 years old.
* Infertility due to male factors, fallopian tube factors, or unknown causes.
* Undergoing IVF in one COS cycle and intended to apply either GnRH antagonist protocol or PPOS protocol
* Voluntary participation in research.
Exclusion Criteria
* Hyperprolactinemia or other endocrine diseases.
* Those who took hormone drugs within the past 3 months
* Suffering from systemic diseases such as kidney failure, lupus erythematosus, depression, etc.
* Abnormal structure of the uterine cavity.
* Patients with endometriosis or cancer
* Random-start cycles.
* Oocyte donation cycles
* Perform embryo biopsy.
20 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hanoi Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thach Than Trong
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thach Than Trong
Role: PRINCIPAL_INVESTIGATOR
Hanoi Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univesity of Medicine and Pharmacy at Ho Chi Minh City
Ho Chi Minh City, , Vietnam
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol, Statistical Analysis Plan, and Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
9720105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.